Claudia Rutherford1, Manish I Patel2,3, Margaret-Ann Tait4, David P Smith5,6,7,8, Daniel S J Costa4,9,10, Shomik Sengupta11,12,13, Madeleine T King4. 1. Faculty of Science, School of Psychology, University of Sydney, Sydney, NSW, Australia. claudia.rutherford@sydney.edu.au. 2. Sydney Medical School, Discipline of Surgery, University of Sydney, Sydney, NSW, Australia. 3. Department of Urology, Westmead Hospital, Westmead, NSW, Australia. 4. Faculty of Science, School of Psychology, University of Sydney, Sydney, NSW, Australia. 5. Cancer Research Division, Cancer Council New South Wales, Sydney, NSW, Australia. 6. Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia. 7. Menzies Health Institute Queensland, Griffith University, Brisbane, Qld, Australia. 8. School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. 9. Pain Management Research Institute, Royal North Shore Hospital, St Leonards, NSW, Australia. 10. Sydney Medical School, Central Clinical School, University of Sydney, Sydney, NSW, Australia. 11. Eastern Health Clinical School, Monash University, Box Hill, Vic, Australia. 12. Department of Urology, Eastern Health, Box Hill, Vic, Australia. 13. ANZUP Cancer Trials Group, Camperdown, NSW, Australia.
Abstract
OBJECTIVE: Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options. METHODS: We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year). RESULTS: Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems. CONCLUSIONS: Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.
OBJECTIVE:Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options. METHODS: We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year). RESULTS: Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems. CONCLUSIONS: Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.
Entities:
Keywords:
Early bladder cancer; Non-muscle invasive bladder cancer; Patient-reported outcomes; Quality of life; Systematic review
Authors: Angela B Smith; Siamak Daneshmand; Sanjay Patel; Kamal Pohar; Edouard Trabulsi; Michael Woods; Tracy Downs; William Huang; Jennifer Taylor; Jeffrey Jones; Michael O'Donnell; Trinity Bivalacqua; Joel DeCastro; Gary Steinberg; Ashish Kamat; Matthew Resnick; Badrinath Konety; Mark Schoenberg; J Stephen Jones; Yair Lotan Journal: BJU Int Date: 2018-08-11 Impact factor: 5.588
Authors: Madelon N M van der Aa; Ewout W Steyerberg; E Fatma Sen; Ellen C Zwarthoff; Wim J Kirkels; Theo H van der Kwast; Marie-Louise Essink-Bot Journal: BJU Int Date: 2007-09-20 Impact factor: 5.588
Authors: Melanie Calvert; Michael Brundage; Paul B Jacobsen; Holger J Schünemann; Fabio Efficace Journal: Health Qual Life Outcomes Date: 2013-10-29 Impact factor: 3.186
Authors: Frederik Wessels; Maximilian Lenhart; Manuel Neuberger; Julia Mühlbauer; Johannes Huber; Johannes Breyer; Philipp Nuhn; Maurice S Michel; Julian Koenig; Maximilian C Kriegmair Journal: World J Urol Date: 2021-05-08 Impact factor: 4.226